1492 Capital Management LLC Invests $1.21 Million in Charles River Laboratories International, Inc. $CRL

1492 Capital Management LLC acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 6,059 shares of the medical research company’s stock, valued at approximately $1,209,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Tema Etfs LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth $26,000. Rothschild Investment LLC increased its holdings in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares in the last quarter. Atlantic Union Bankshares Corp bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $31,000. Activest Wealth Management raised its position in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares during the period. Finally, Elyxium Wealth LLC purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $46,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on CRL. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Mizuho set a $192.00 price target on Charles River Laboratories International in a report on Friday, May 8th. CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and upped their price target for the stock from $167.00 to $219.00 in a research note on Friday, May 29th. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Monday, April 13th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $208.50.

Charles River Laboratories International Stock Up 3.0%

Shares of CRL opened at $180.10 on Thursday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The stock has a market capitalization of $8.68 billion, a price-to-earnings ratio of -47.90, a price-to-earnings-growth ratio of 2.00 and a beta of 1.46. Charles River Laboratories International, Inc. has a 1 year low of $138.81 and a 1 year high of $228.88. The business’s 50 day simple moving average is $170.53 and its 200-day simple moving average is $181.44.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. Charles River Laboratories International’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the firm posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.